Positive data from Phase III True North Trial of ozanimod in adults with moderate to severe ulcerative colitis

The study met both primary endpoints, clinical remission vs placebo at induction at week 10 (18.4% vs 6.0%; p<0.0001) and maintenance at week 52 (37.0% vs 18.5%; p<0.0001); and several key secondary endpoints; clinical response, endoscopic improvement and mucosal healing.

Source:

Biospace Inc.

Resource links:

Ozanimod is an oral selective sphingosine 1-phosphate 1 receptor (S1P1R) modulator currently being investigated for ulcerative colitis and Crohns disease.